Consensus Recommendations on the Management of Toxicity Associated with CD3xCD20 Bispecific Antibody Therapy.
Publication Title
Blood
Document Type
Article
Publication Date
1-22-2024
Keywords
swedish; swedish cancer; washington
Abstract
Bispecific antibodies (BsAb) that target CD3 and CD20 represent a new milestone in the treatment of patients with B-cell non-Hodgkin lymphoma. These drugs have demonstrated remarkable single-agent activity in heavily pretreated patients, and at least three have so far received regulatory approvals in various countries. However, BsAbs can lead to potentially severe toxicity associated with T-cell activation, particularly cytokine release syndrome (CRS). The anticipated widespread use of these off-the-shelf products poses challenges for implementation and highlights the need for guidance in anticipating, mitigating, and managing adverse events. In clinical trials, guidance for the evaluation and treatment of CRS and neurotoxicity associated with BsAb therapy have been modeled after algorithms originally created for chimeric antigen receptor (CAR) T-cell therapies and other immune effector therapies. Yet notable differences in timing, quality, and severity exist between the toxicities of BsAbs and CAR T-cell therapies. We therefore convened an international panel of academic and community practice physicians, advanced practitioners, registered nurses, and pharmacists with experience using CD3xCD20 BsAbs in clinical trial and off-trial settings to provide comprehensive, consensus-based recommendations specific to the assessment and management of CD3xCD20 BsAb-related toxicities.
Clinical Institute
Cancer
Specialty/Research Institute
Oncology
Specialty/Research Institute
Hematology
DOI
10.1182/blood.2023022432
